Endo International PLC (NASDAQ:ENDP) Expected to Post Earnings of $0.47 Per Share

Wall Street brokerages expect Endo International PLC (NASDAQ:ENDP) (TSE:ENL) to post earnings per share of $0.47 for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Endo International’s earnings, with estimates ranging from $0.40 to $0.52. Endo International posted earnings per share of $0.76 in the same quarter last year, which indicates a negative year over year growth rate of 38.2%. The business is expected to issue its next quarterly earnings report on Wednesday, August 14th.

According to Zacks, analysts expect that Endo International will report full year earnings of $2.17 per share for the current financial year, with EPS estimates ranging from $2.10 to $2.25. For the next financial year, analysts forecast that the business will report earnings of $2.41 per share, with EPS estimates ranging from $1.72 to $3.15. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its earnings results on Thursday, May 9th. The company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.11. The firm had revenue of $720.00 million for the quarter, compared to analysts’ expectations of $692.31 million. Endo International had a negative net margin of 18.35% and a negative return on equity of 199.18%. The business’s revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.67 EPS.

A number of analysts recently weighed in on ENDP shares. Canaccord Genuity set a $17.00 price objective on shares of Endo International and gave the stock a “buy” rating in a research report on Friday, March 8th. BidaskClub raised shares of Endo International from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. SunTrust Banks started coverage on shares of Endo International in a research report on Tuesday, March 19th. They issued a “buy” rating and a $13.00 price objective on the stock. Barclays initiated coverage on shares of Endo International in a research report on Tuesday. They issued an “equal weight” rating and a $6.00 price objective on the stock. Finally, ValuEngine raised shares of Endo International from a “sell” rating to a “hold” rating in a research report on Tuesday, March 12th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and six have issued a buy rating to the company. Endo International presently has an average rating of “Hold” and an average price target of $13.57.

Endo International stock traded down $0.23 during midday trading on Friday, reaching $4.24. The stock had a trading volume of 64,645 shares, compared to its average volume of 3,894,259. Endo International has a 52-week low of $4.18 and a 52-week high of $18.50. The firm has a market capitalization of $1.01 billion, a P/E ratio of 1.47 and a beta of 1.35.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENDP. LS Investment Advisors LLC bought a new position in shares of Endo International during the fourth quarter valued at approximately $59,000. Oregon Public Employees Retirement Fund bought a new position in shares of Endo International during the fourth quarter valued at approximately $76,000. Signition LP acquired a new stake in Endo International in the first quarter valued at approximately $139,000. Neuburgh Advisers LLC boosted its stake in Endo International by 13.9% in the fourth quarter. Neuburgh Advisers LLC now owns 24,860 shares of the company’s stock valued at $181,000 after acquiring an additional 3,036 shares in the last quarter. Finally, Factorial Partners LLC acquired a new stake in Endo International in the first quarter valued at approximately $193,000. Hedge funds and other institutional investors own 93.59% of the company’s stock.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Recommended Story: What does an outperform rating mean?

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.